Fingolimod: Advantages for some children and adolescents with highly active RRMS
Since 2018, the immunosuppressant drug fingolimod has also been approved for children and adolescents aged 10 years and older whose relapsing remitting multiple sclerosis (RRMS) is highly active or severe and rapidly evolving. ...
Jun 24, 2019
0
0